China’s National Medical Products Administration approved Lilly’s shot for long-term weight management on Friday, the company said in a statement on its official WeChat account, less than two ...

Eli Lilly did not specify when sales of the drug would begin in China, or how many doses would be sold, according to Reuters. The drugmaker did not immediately respond to Investopedia 's request ...

Eli Lilly (NYSE: LLY) has achieved a major milestone by securing regulatory approval for its weight management drug, Mounjaro, in China. This development, confirmed through the company’s ...

AstraZeneca spinout Dizal Pharmaceuticals won an FDA accelerated approval for sunvozertinib for previously treated EGFR ex 20-mutated non-small cell lung cancer. To be marketed as Zegfrovy, the oral ...

Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

the emergence of a viable local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could make weight loss drugs more accessible in the world’s second-largest economy. China’s nascent weight ...

Eli Lilly, the global pharmaceutical giant, said the Therapeutic Goods Administration had approved the use of its Mounjaro weight-loss drug to treat moderate-to-severe obstructive sleep apnoea in ...

Tirzepatide is the active ingredient in Lilly’s injectable diabetes drug Mounjaro and weight-loss drug Zepbound. Mounjaro previously was approved in China for diabetes treatment.

SHANGHAI (Reuters) -Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish ...